Developmental Funds

Druker, Brian J.

Abstract

Developmental funds controlled by the Director are derive from institutional sources, including Knight Cancer Institute funds raised through the OHSU Foundation, contributions from the OHSU Hospital and Clinics and the School of Medicine, and the support from our CCSG. The Director has formal authority for all cancer related funds raised by the OHSU Foundation. The Knight Cancer Institute has used developmental funds from philanthropic sources as well as CCSG support to: recruit new faculty, support pilot projects, establish new Shared Resources, and provide support for technological and resource enhancements within the Shared Resources. In the last funding period, the OHSU development staff raised $33,000,000 in philanthropic contributions with an additional $98,000,000 gift that will be distributed over the next 5 - 7 years. Additionally, three endowed faculty positions have been established. The Knight has used CCSG funds, matched with philanthropic funds to support pilot projects, career development awards and bridge funding. The goal of this support has been to provide critical resources for cancer investigators to obtain preliminary funding for external peer-reviewed funding and to encourage innovative cancer research projects. A total of $668,000 of pilot project and career development award funding have been distributed over the past five years. These funds have contributed to over $20.9 million of external peer-reviewed funding. Development funds have been utilized to strengthen shared resources, as well as support women accruals to clinical trials. Over the past funding period shared resources have been invested in heavily to expand services offered, upgrade instrumentation, and ensure that sen/ices offered remain state-of-the art. To support accrual of women to clinical trials, funds were spent for recruitment of faculty specializing in female oncologic diseases, and infrastructure support for the Clinical Research Management Shared Resource.

Public Health Relevance

The Knight Cancer Institute has used developmental funds from philanthropic sources as well as CCSG support to: recruit new faculty, support pilot projects, establish new Shared Resources, and provide support for technological and resource enhancements within the Shared Resources.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Center Core Grants (P30)
• Project #: 5P30CA069533-17
• Application #: 8712374
• Study Section: Subcommittee B - Comprehensiveness (NCI)
• Budget Start: 2014-07-01
• Budget End: 2015-06-30
• Support Year: 17
• Fiscal Year: 2014

Institution

• Name: Oregon Health and Science University
• City: Portland
• State: OR
• Country: United States
• Zip Code: 97239

Publications

Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074

Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96

Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019

Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019

Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6

Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296

Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482

Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028

Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188

Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6